Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oruka Therapeutics, Inc. Director's Dealing 2012

Feb 15, 2012

32280_dirs_2012-02-14_1d35630a-2529-42ca-ae0e-cfeea826d1ab.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-02-10

Reporting Person: BREWER RICHARD B (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-02-10 Option to Purchase Common Stock $1.00 A 3500 Acquired 2022-02-10 Common Stock (3500) Direct
2012-02-10 Option to Purchase Common Stock $1.00 A 3500 Acquired 2022-02-10 Common Stock (3500) Direct

Footnotes

F1: The options vest in 12 equal monthly installments measured from 1/1/12. If the Reporting Person's service as a director of the Issuer terminates in connection with or at anytime following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.